Rhumbline Advisers Purchases 154,826 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD)

Rhumbline Advisers increased its stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 1,289.8% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 166,830 shares of the company’s stock after buying an additional 154,826 shares during the period. Rhumbline Advisers owned 0.30% of Prelude Therapeutics worth $213,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in PRLD. Massachusetts Financial Services Co. MA boosted its stake in Prelude Therapeutics by 5.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 549,530 shares of the company’s stock valued at $1,138,000 after purchasing an additional 27,155 shares during the last quarter. Geode Capital Management LLC raised its holdings in Prelude Therapeutics by 8.2% in the 3rd quarter. Geode Capital Management LLC now owns 391,716 shares of the company’s stock worth $811,000 after purchasing an additional 29,765 shares during the period. State Street Corp raised its holdings in Prelude Therapeutics by 35.1% in the 3rd quarter. State Street Corp now owns 286,046 shares of the company’s stock worth $592,000 after purchasing an additional 74,300 shares during the period. Jacobs Levy Equity Management Inc. raised its holdings in Prelude Therapeutics by 885.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 174,979 shares of the company’s stock worth $362,000 after purchasing an additional 157,218 shares during the period. Finally, Walleye Capital LLC raised its holdings in Prelude Therapeutics by 446.2% during the third quarter. Walleye Capital LLC now owns 83,175 shares of the company’s stock valued at $172,000 after acquiring an additional 67,946 shares during the period. Hedge funds and other institutional investors own 79.72% of the company’s stock.

Wall Street Analyst Weigh In

Separately, JMP Securities reissued a “market outperform” rating and set a $4.00 price target (down from $7.00) on shares of Prelude Therapeutics in a report on Wednesday, December 11th.

Insider Buying and Selling at Prelude Therapeutics

In other news, CEO Krishna Vaddi acquired 100,000 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was purchased at an average price of $0.93 per share, for a total transaction of $93,000.00. Following the completion of the transaction, the chief executive officer now directly owns 1,167,275 shares in the company, valued at approximately $1,085,565.75. This trade represents a 9.37 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Andrew Combs acquired 60,000 shares of the business’s stock in a transaction dated Monday, December 23rd. The shares were purchased at an average price of $1.37 per share, with a total value of $82,200.00. Following the transaction, the insider now owns 377,623 shares of the company’s stock, valued at approximately $517,343.51. This represents a 18.89 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 198,075 shares of company stock valued at $213,486 over the last ninety days. 62.80% of the stock is currently owned by company insiders.

Prelude Therapeutics Stock Down 9.0 %

NASDAQ:PRLD opened at $0.67 on Tuesday. The business’s 50-day simple moving average is $1.02 and its two-hundred day simple moving average is $1.71. The stock has a market cap of $36.87 million, a PE ratio of -0.38 and a beta of 1.43. Prelude Therapeutics Incorporated has a 52 week low of $0.67 and a 52 week high of $6.80.

Prelude Therapeutics Company Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.